Developing drug therapies in bronchiectasis

Expert Opinion on Investigational Drugs

Volumn 24, Issue 2, 2015, Pages 169-181

  Sidhu, Manjit K ^a,b   Mandal, Pallavi ^a   Hill, Adam T ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Anti inflammatory; Antibiotics; Bronchiectasis; Mucoactive; Pharmacotherapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; IMMUNOSTIMULATING AGENT; MUCOLYTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL THERAPY; B LYMPHOCYTE; BACTERIAL CLEARANCE; BACTERIAL LOAD; BREATHING EXERCISE; BRONCHIECTASIS; CD4+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; LONG TERM CARE; LUNG FUNCTION; MUCOCILIARY CLEARANCE; MULTICENTER STUDY (TOPIC); NEUTROPHIL CHEMOTAXIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; VACCINATION; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG EFFECTS; INFLAMMATION; PATHOPHYSIOLOGY;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; BRONCHIECTASIS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; INFLAMMATION; MUCOCILIARY CLEARANCE;

EID: 84921310705     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.971153     Document Type: Review

References (60)

1. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010(65 Suppl 1):i1-58
2. Bilton D, Jones AL. Chapter 1: bronchiectasis: epidemiology and causes. In: Floto RA, Haworth CS, editors. Bronchiectasis. European Respiratory Society; Lausanne, Switzerland: 2011. Published online May 26, 2011; doi:10.1183/1025448x.10003110
3. Weycker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005;12(4):205-9
4. Reid LM. Reduction in bronchial subdivision in bronchiectasis. Thorax 1950;5(3):233-47
5. Chalmers JD, Smith MP, McHugh BJ, et al. Short-and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012;186(7):657-65
6. O'Donnell AE. Bronchiectasis. CHEST J 2008;134(4):815-23
7. Kelly MG, Murphy S, Elborn JS. Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. Eur J Intern Med 2003;14(8):488-92
8. Nicotra MB, Rivera M, Dale AM, et al. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995;108(4):955-61
9. Cole P. Host-microbe relationships in chronic respiratory infection. Respiration 1989(55 Suppl 1):5-8
10. Angrill J, Agusti C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002;57(1):15-19
11. Hill AT, Welham S, Reid K, Bucknall CE. British thoracic society national bronchiectasis audit 2010 and 2011. Thorax 2012;67:928-30
12. Wilson CB, Jones PW, O'Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997;10(8):1754-60
13. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007;132(5):1565-72
14. Evans SA, Turner SM, Bosch BJ, et al. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J 1996;9(8):1601-4
15. MacLeod DL, Barker LM, Sutherland JL, et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 2009;64(4):829-36
16. O'Donnell AE, Swarnakar R, Yahina L, et al. A placebo-controlled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectatic patients with chronic Pseudomonas aeruginosa lung infection. Eur Respir J 2009;34:231S
17. Hill A, Bilton D, Brown J, et al. British thoracic society quality standards for clinically significant bronchiectasis in adults July 2012. Br Thorac Soc Rep 2012;4:1-16
18. Malakhov MP, Aschenbrenner LM, Smee DF, et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006;50:1470-9
19. Nicholls JM, Aschenbrenner LM, Paulson JC, et al. Comment on: concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza. J Antimicrob Chemother 2008;62:426-8
20. Triana-Baltzer GB, Gubareva LV, Nicholls JM, et al. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181; a sialidase fusion protein. PLoS One 2009;4(11):e7788
21. Emmerich B, Emslander HP, Pachmann K, et al. Local immunity in patients with chronic bronchitis and the effects of a bacterial extract, Bronco-AvxomR, on T-lymphocytes, macrophages, gamma-interferon and secretory immunoglobulin A in bronchoalveolar lavage fluid and other variables. Respiration 1990;57:90-9
22. Collet JP, Shapiro P, Ernst P, et al. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. Am J Respir Crit Care Med 1997;156(6):1719-24
23. Orcel B, Delclaux B, Baud M, et al. Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. Eur Respir J 1994;7(3):446-52
24. Soler M, Mutterlein R, Cozma G. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration 2007;74(1):26-32
25. Sadowska A, Verbraecken J, Darquennes K, De Backer WA. Role of N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis 2006;1(4):425-34
26. Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2014;2(3):187-94
27. Turner RD, Bothamley GH. N-acetylcysteine for COPD: the evidence remains inconclusive. Lancet Respir Med 2014;2(4):e3
28. Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012;205(1):13-19
29. Shyamsundar M, McKeown ST, O'Kane CM, et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 2009;179(12):1107-14
30. Mandal P, Chalmers JD, Graham C, et al. Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respir Med 2014;2(6):455-63
31. www.nice.org.uk/asthma
32. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007;175(3):235-42
33. Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002;99(13):8921-6
34. Milara J, Lluch J, Almudever P, et al. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2014;134(2):314-22
35. Llewellyn-Jones CG, Johnson MM, Mitchell JL, et al. In vivo study of indomethacin in bronchiectasis: effect on neutrophil function and lung secretion. Eur Respir J 1995;8(9):1479-87
36. Stockley R, De Soyza A, Gunawardena K, et al. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med 2013;107(4):524-33
37. Cobanoglu N, Ozcelik U, Gocmen A, et al. Antioxidant effect of beta-carotene in cystic fibrosis and bronchiectasis: clinical and laboratory parameters of a pilot study. Acta Paediatrica 2002;91(7):793-8
38. Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med 2005;99(1):27-31
39. Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011;105(12):1831-5
40. Nicolson CH, Stirling RG, Borg BM, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012;106(5):661-7
41. Daviskas E, Anderson SD, Gomes K, et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology (Carlton, Vic) 2005;10(1):46-56
42. Daviskas E, Anderson SD, Eberl S, et al. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur Respir J 2008;31(4):765-72
43. Bilton D, Daviskas E, Anderson SD, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013;144(1):215-25
44. Daviskas E, Anderson SD, Eberl S, et al. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999;159(6):1843-8
45. Daviskas E, Anderson SD, Gomes K. Increase in health status after 12 days treatment with inhaled mannitol in patients with bronchiectasis. Eur Respir J 2003;22:Suppl 45:p. 430
46. Daviskas E, Anderson SD, Eberl S, et al. The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest 2001;119(2):414-21
47. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012;380(9842):660-7
48. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013;309(12):1260-7
49. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013;309(12):1251-9
50. Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011;183(4):491-9
51. Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014;189(8):975-82
52. Barker AF, O'Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014;2(9):738-49
53. Mandal P, Sidhu MK, Donaldson LS, et al. Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis. QJM 2013;106(1):27-33
54. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human dnase. Chest 1998;113:1329-34
55. Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013;41(5):1107-15
56. Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013;68(9):812-17
57. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162(2 Pt 1):481-5
58. Drobnic ME, Sune P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39(1):39-44
59. Bilton D, Henig N, Morrissey B, et al. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006;130(5):1503-10
60. Tamaoki J, Chiyotani A, Kobayashi K, et al. Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis. Am Rev Respir Dis 1992;145(3):548-52